These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30830216)
1. Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials. Garmendia CA; Nassar Gorra L; Rodriguez AL; Trepka MJ; Veledar E; Madhivanan P JAMA Intern Med; 2019 Apr; 179(4):582-584. PubMed ID: 30830216 [TBL] [Abstract][Full Text] [Related]
4. The FDA and IBS drug development. Mangel AW Am J Gastroenterol; 2009 Dec; 104(12):3106; author reply 3106. PubMed ID: 19956135 [No Abstract] [Full Text] [Related]
5. A proposal for radical changes in the drug-approval process. Wood AJ N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784 [No Abstract] [Full Text] [Related]
6. Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia. Talley NJ Am J Gastroenterol; 2009 Jun; 104(6):1339-41. PubMed ID: 19491845 [No Abstract] [Full Text] [Related]
7. FDA seeks swifter approval of drugs for some life-threatening or debilitating diseases. Marwick C JAMA; 1988 Nov; 260(20):2976. PubMed ID: 3184360 [No Abstract] [Full Text] [Related]
8. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Martin MT; Nutescu EA Curr Med Res Opin; 2011 Nov; 27(11):2123-31. PubMed ID: 21942466 [TBL] [Abstract][Full Text] [Related]
9. [Pharmacological properties and clinical efficacy of apixaban (Eliquis(®)]. Imai N; Fujii Y; Amano M Nihon Yakurigaku Zasshi; 2013 Nov; 142(5):247-54. PubMed ID: 24212595 [No Abstract] [Full Text] [Related]
10. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA. Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815 [TBL] [Abstract][Full Text] [Related]
11. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692 [TBL] [Abstract][Full Text] [Related]
12. FDA approval signals more 'homework' on the horizon in trials. Waters H Nat Med; 2011 Jul; 17(7):754. PubMed ID: 21738130 [No Abstract] [Full Text] [Related]
13. Drug development process for a product with a primary pediatric indication. Allen AJ; Michelson D J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061 [TBL] [Abstract][Full Text] [Related]
15. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations. Akwaa F; Spyropoulos AC Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963 [TBL] [Abstract][Full Text] [Related]
16. The special treatment. Osborne R Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770 [No Abstract] [Full Text] [Related]
17. Errors in 'Trials and error'. Miller DD Nat Biotechnol; 2006 Jul; 24(7):747. PubMed ID: 16841048 [No Abstract] [Full Text] [Related]
18. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation. DeLoughery EP; Prasad V Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605 [No Abstract] [Full Text] [Related]
19. Treatment research at the millennium: from efficacy to effectiveness. Lebowitz BD; Rudorfer MV J Clin Psychopharmacol; 1998 Feb; 18(1):1. PubMed ID: 9472835 [No Abstract] [Full Text] [Related]
20. Andexxa--an antidote for apixaban and rivaroxaban. Med Lett Drugs Ther; 2018 Jun; 60(1549):99-101. PubMed ID: 29913471 [No Abstract] [Full Text] [Related] [Next] [New Search]